We are live on ! Find out more
AVTX icon

Avalo Therapeutics
AVTX

43 hedge funds and large institutions have $10.9M invested in Avalo Therapeutics in 2022 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 4 increasing their positions, 18 reducing their positions, and 27 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% less ownership

Funds ownership: 0.02% → 0.02% (-0%)

34% less funds holding

Funds holding: 65 → 43 (-22)

78% less first-time investments, than exits

New positions opened: 6 | Existing positions closed: 27

78% less repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 18

81% less capital invested

Capital invested by funds: $56.2M → $10.9M (-$45.2M)

Holders
43
Holders Change
-22
Holders Change %
-33.85%
% of All Funds
0.72%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
6
Increased
4
Reduced
18
Closed
27
Calls
$7K
Puts
–
Net Calls
+$7K
Net Calls Change
+$13K

Top Buyers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
+$470K
2
E
Ergoteles
New York
+$132K
3
Goldman Sachs
Goldman Sachs
New York
+$58.9K
4
Citadel Advisors
Citadel Advisors
Florida
+$28.1K
5
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT)
United Kingdom
+$20.1K

Top Sellers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
-$1.17M
2
BFM
Boothbay Fund Management
New York
-$869K
3
IC
Ikarian Capital
Texas
-$554K
4
IHAM
Integral Health Asset Management
New York
-$507K
5
OM
Opaleye Management
Massachusetts
-$467K
Name Holding Trade Value Shares
Change 		Change in
Stake
Creative Planning
26
Creative Planning
Kansas
$10K – – –
MAM
27
Meeder Asset Management
Ohio
$9K – – –
Victory Capital Management
28
Victory Capital Management
Texas
$8K – – –
Balyasny Asset Management
29
Balyasny Asset Management
Illinois
$8K +$8.03K +6 New
APP
30
Avantax Planning Partners
Iowa
$6K – – –
MFA
31
Mayflower Financial Advisors
Massachusetts
$5K – – –
MLL
32
Moody Lynn & Lieberson
Massachusetts
$5K – – –
UBS Group
33
UBS Group
Switzerland
$4K -$6.69K -5 -63%
CSS
34
Cubist Systematic Strategies
Connecticut
$3K +$1.34K +1 +100%
Legal & General Group
35
Legal & General Group
United Kingdom
$2K -$1.34K -1 -50%
Royal Bank of Canada
36
Royal Bank of Canada
Ontario, Canada
$2K – – –
TWA
37
TCI Wealth Advisors
Arizona
$2K – – –
WT
38
Washington Trust
Rhode Island
$2K – – –
JP Morgan Chase
39
JP Morgan Chase
New York
$1K -$12K -9 -90%
Group One Trading
40
Group One Trading
Illinois
$1K -$1.34K -1 -50%
Citigroup
41
Citigroup
New York
$1K – – –
Fidelity Investments
42
Fidelity Investments
Massachusetts
$1K – – –
PHK
43
Point72 Hong Kong
Hong Kong
$1K – – –
BFM
44
Boothbay Fund Management
New York
– -$869K -416 Closed
IC
45
Ikarian Capital
Texas
– -$554K -265 Closed
IHAM
46
Integral Health Asset Management
New York
– -$507K -243 Closed
N
47
Nuveen
North Carolina
– -$294K -141 Closed
Two Sigma Advisers
48
Two Sigma Advisers
New York
– -$152K -73 Closed
Deutsche Bank
49
Deutsche Bank
Germany
– -$82K -39 Closed
Two Sigma Investments
50
Two Sigma Investments
New York
– -$51K -25 Closed
1
2
3

AVTX Hedge Fund Activity: Q2 2022 in Review

43 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Avalo Therapeutics (AVTX) for Q2 2022, worth a combined $10.9M — down 81% from $56.2M a quarter earlier.

Sellers outnumbered buyers: 27 funds closed out of AVTX and 6 opened new positions — a net loss of 21 holders — while 18 trimmed existing stakes and 4 added.

The largest buyer was Millennium Management, opening a new position worth an estimated $470K. The largest seller was BlackRock, cutting an estimated $1.17M.

  • 43 institutional investors held Avalo Therapeutics (AVTX) as of Q2 2022, down from 65 in Q1 2022.
  • Funds reported $10.9M of Avalo Therapeutics stock for Q2 2022, down 81% quarter-over-quarter.
  • 6 funds opened new Avalo Therapeutics positions in Q2 2022 and 27 closed out, a net change of -21 holders.
  • The largest Avalo Therapeutics buyer in Q2 2022 was Millennium Management, an estimated $470K added.
  • The largest Avalo Therapeutics seller in Q2 2022 was BlackRock, an estimated $1.17M sold.

Based on aggregated 13F filings for Q2 2022.